The CKB team is hiring! We're looking for part-time Clinical Content Curators to join the team---> Check out the job listing here!
It's time for the next quarterly update to the CKB CORE gene list! This quarter we are highlighting tumor suppressor genes. For more information about the tumor suppressor genes available, check out the latest CKB CORE quarterly newsletter here. Have questions or comments? Email us at firstname.lastname@example.org
Exciting news! CKB CORE and BOOST now include clinical trial locations and contact details! Need more information or have questions? Email us at email@example.com.
CKB UPDATE! CORE and BOOST now include transcripts with version numbers. Questions? Feel free to contact us at firstname.lastname@example.org.
New FDA approval for Atezolizumab plus Cobimetinib and Vemurafenib for patients with BRAF V600-positive advanced melanoma! Find more information on this in CKB CORE. Need up-to-date information on other FDA drug approvals? Consider a CKB BOOST subscription, which includes full access to all drugs and their FDA approvals, along with related content!
CKB BOOST now has AMP/CAP/ASCO evidence level coding!
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.